Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199Sylvia Adams, Sunil Badve|Journal of Clinical Oncology|2014Cited by 1.3k
The Intestinal Microbiome and Estrogen Receptor–Positive Female Breast CancerMaryann Kwa, Sylvia Adams|JNCI Journal of the National Cancer Institute|2016Cited by 521
Current Landscape of Immunotherapy in Breast CancerSylvia Adams, Elizabeth A. Mittendorf, Margaret E. Gatti‐Mays et al.|JAMA Oncology|2019Cited by 409
Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Clinical Cancer Research|2012Cited by 225
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130H. S. Rugo, Leisha A. Emens, Sherene Loi et al.|Annals of Oncology|2019Cited by 115